OHSU

IRB #

IRB00010170

Title

A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of the study is to compare the effects, good and bad, of the study drug (MORAb-004) in combination with gemcitabine and docetaxel with gemcitabine and docetaxel alone.

Medical Condition(s)

Locally advanced unresectable or metastatic soft tissue sarcoma

Eligibility Criteria

Age 18 or over diagnosed with locally advanced unresectable or metastatic soft tissue sarcoma with no, one, or two prior systemic treatments. Blood work, imaging, and heart scans will be performed to determine eligibility upon consent.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Treatment will last for as long as the participant is seeing clinical benefit.

Minors Included

No

Contact

David Boody-Alter
503-418-9655
boodyalt@ohsu.edu

Sponsor

Morphotek, Inc.

Recruitment End

10/29/2015

Compensation Provided

No


Go Back